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Abstract
Background: Patients with non-ST-segment elevation myocardial infarction
(NSTEMI) have a generally poor prognosis and antithrombotic management patterns
(AMPs) used post-acute coronary syndrome (ACS) remain unclear. Duration of dual
antiplatelet therapy (DAPT) and patient characteristics was evaluated in NSTEMI
patients enrolled in EPICOR Asia.
Hypothesis: Patients stopping DAPT early may benefit from more intensive
monitoring.
Methods: EPICOR Asia was a prospective, real-world, primary data collection, cohort
study in adults with an ACS, conducted in eight countries/regions in Asia, with 2 year
follow-up. Eligible patients were hospitalized within 48 hours of symptom onset and
survived to discharge. We describe AMPs and baseline characteristics in NSTEMI
patients surviving ≥12 months with DAPT duration ≤12 and > 12 months post-dis-
charge. Clinical outcomes (composite of death, myocardial infarction, and stroke; and
bleeding) were also explored.
Results: At discharge, 90.8% of patients were on DAPT (including clopidogrel, 99%).
At 1- and 2-year follow-up, this was 79.2% and 60.0%. Patients who stopped DAPT
≤12 months post-discharge tended to be older, female, less obese, have prior cardio-
vascular disease, and have renal dysfunction. While causality cannot be inferred, the
incidence of the composite endpoint over the subsequent 12 months was 10.6% and
3.1% with shorter vs longer use of DAPT, and mortality risk over the same period
was 8.4% and 1.6%.
Conclusions: Over 90% of NSTEMI patients were discharged on DAPT, with 60% on
DAPT at 2 years. Patients stopping DAPT early were more likely to have higher base-
line risk and may therefore benefit from more intensive monitoring during long-term
follow-up.
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1 | INTRODUCTION
Despite advances in medical and invasive management strategies for
patients with coronary heart disease (CHD), recent results from the
Global Burden of Disease Study showed that CHD remained the lead-
ing cause of premature death worldwide in 2016, with an age-
standardized mortality rate of 149.7 per 100 000.1 While mortality
from CHD has progressively declined since 1990 in middle- and high-
income countries, it has increased in low-income regions.1 Suggested
causes include the growing proportion of people aged ≥60 years, life-
style factors (such as tobacco and alcohol use, and increasing consump-
tion of foods with high energy/fat content), lack of preventative
measures, low availability of CHD management, and lack of rehabilita-
tion and secondary prevention programmes.2,3 In fact, increasingly
westernized lifestyles have been implicated in the increasing prevalence
of overweight, diabetes, and associated cardiovascular diseases (CVD)
among affluent people within low- to middle-income countries.3
In the United States, approximately 70% of patients presenting with
an acute coronary syndrome (ACS) have a non-ST-segment elevation
(NSTE)-ACS, comprising non-ST-segment elevation myocardial infarc-
tion (NSTEMI) and unstable angina (UA), and only 30% have an ST-
segment elevation myocardial infarction (STEMI).4 In Asia, the ratio is
reversed, with 60-80% of patients presenting with STEMI, but there is
evidence that the proportion of Asian patients with NSTE-ACS is grow-
ing.5 Furthermore, although short-term mortality is higher with STEMI,
the risk of death during long-term follow-up is greater with NSTEMI.6,7
Recent guidelines in the United States and Europe include a class
1 recommendation for 12 months of dual antiplatelet therapy (DAPT)
with aspirin and a P2Y12 inhibitor following ACS.
4,8,9 However, in some
populations with high risk, 12 months' duration of DAPT is not long
enough. The subgroup analysis of the Clopidogrel for High Ath-
erothrombotic Risk and Ischemic Stabilization, Management, and
Avoidance trial showed that patients with clinically evident
atherothrombosis (documented prior MI, ischemic stroke, or symptom-
atic peripheral artery disease) benefitted from long-term DAPT (median
duration 27.6 months) beyond aspirin alone.10,11 Another trial,
PEGASUS-TIMI 54 (Prior Heart Attack Using Ticagrelor Compared to
Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarc-
tion 54) showed that in patients with a MI more than 1 year previously,
treatment with long-term DAPT (median duration 33 months) signifi-
cantly reduced the risk of cardiovascular (CV) death, MI, or stroke com-
pared with aspirin therapy alone.12 Several meta-analyses and a
systematic review of randomized trials have also indicated that
prolonging DAPT to more than 1 year following myocardial infarction
(MI) can reduce CV event rates, although at the risk of increased (non-
fatal) bleeding.13-16 However, the benefits of continuing DAPT beyond
a year in real-world populations are less well defined, and there is
relatively little evidence from Asian countries. The EPICOR Asia (long-
tErm follow-uP of antithrombotic management patterns In Acute COR-
onary syndrome patients in Asia) study was an observational, primary
data collection study designed to investigate acute and long-term anti-
thrombotic management patterns (AMPs) in ACS survivors. The aim of
this analysis was to evaluate long-term use of DAPT, and baseline
patient characteristics associated with earlier DAPT discontinuation vs
>12 months of DAPT, in patients with NSTEMI.
2 | METHODS
2.1 | Study design and patients
EPICOR Asia (NCT01361386; https://clinicaltrials.gov/ct2/show/
NCT01361386?term=01361386&rank=1) was a prospective, real-
world, cohort study with a 2 year follow-up period in patients surviv-
ing the initial hospitalization for an ACS. Full details of the study
design have been published previously.17 Briefly, between June 2011
and May 2012, patients were enrolled at discharge from 218 centers
in China, Hong Kong, India, Malaysia, Singapore, South Korea,
Thailand, and Vietnam. Male and female patients were eligible for
inclusion if they were aged ≥18 years, were hospitalized within
48 hours of symptom onset, survived to discharge, and had a final
diagnosis of STEMI, NSTEMI, or UA. Patients with a secondary ACS
(ie, precipitated by or occurring as a complication of another event,
such as surgery, trauma, or percutaneous coronary intervention [PCI])
were excluded from the study. Baseline and in-hospital data were col-
lected retrospectively for the index event up to hospital discharge,
and prospectively by means of telephone interviews at 6 weeks then
every 3 months up to 2 years.
All patients provided written informed consent to participate in
the study and agreed to follow-up interviews. The study was con-
ducted in accordance with ethical principles that are consistent with
the Declaration of Helsinki revision, International Conference on Har-
monization Good Clinical Practice guidelines, and the applicable legis-
lation on non-interventional studies, and written approval was
obtained from the relevant local Ethics Committees and/or Regulatory
Authorities.
2.2 | Objectives
The primary objective of EPICOR Asia was to describe acute and
long-term AMPs in ACS survivors across a range of clinical settings in
the eight different countries/regions in Asia. The objectives of the
present post hoc analysis were to evaluate reported use of AMPs at
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discharge and during follow-up in the sub-population of patients with
NSTEMI and to investigate possible differences in baseline character-
istics according to DAPT duration ≤12 months vs >12 months up to
the final follow-up at 2 years in patients discharged on DAPT who
survived ≥12 months post-discharge. The incidence of major adverse
CV events (composite of death, MI, and ischemic stroke; and death as
an individual outcome) and major bleeding events during the second
year post-discharge by DAPT duration ≤12 vs >12 months is also
described. In practice, final interviews were conducted within
±2 weeks of the 24-month time point. Outcomes data are provided
based on cumulative summary at pre-defined intervals during
follow-up.
TABLE 1 Baseline demographic and socioeconomic characteristics of NSTEMI patients who survived ≥12 months and received DAPT for
≤12 months vs >12 months post-dischargea
Characteristic
DAPT durationa
P value≤12 months (n = 299) >12 months (n = 1825)
Age group, years <.05
≤59 117 (39.1) 798 (43.7)
60-74 118 (39.5) 748 (41.0)
≥75 64 (21.4) 279 (15.3)
Male 205 (68.6) 1382 (75.7) <.01
BMI, kg/m2, mean (SD) 24.4 (3.5) 24.8 (3.7) .12
Any CVD risk factorsb 211/297 (71.0) 1300/1818 (71.5) .87
Hypertension 177/297 (59.6) 1068/1815 (58.8) .81
Hypercholesterolemia 72/288 (25.0) 362/1765 (20.5) .08
Diabetes 68/295 (23.1) 548/1799 (30.5) <.01
Family history of CHD 34/284 (12.0) 172/1702 (10.1) .34
Current smoker 99/299 (33.1) 616/1825 (33.8) .93
Obesity 113/292 (38.7) 726/1690 (43.0) .17
Any previous CVDb 102/297 (34.3) 502/1783 (28.2) <.05
Myocardial infarction 36/297 (12.1) 191/1773 (10.8) .49
Prior PCI 26/297 (8.8) 150/1781 (8.4) .85
Prior CABG 4/297 (1.4) 41/1780 (2.3) .30
Coronary angiogram diagnostic for CAD 37/297 (12.5) 169/1773 (9.5) .12
Angina 50/297 (16.8) 239/1777 (13.5) .12
Heart failure 12/294 (4.1) 52/1777 (2.9) .29
Atrial fibrillation 8/296 (2.7) 32/1776 (1.8) .30
TIA/stroke 17/296 (5.7) 89/1778 (5.0) .59
Peripheral vascular disease 3/294 (1.0) 18/1776 (1.0) .99
Chronic renal failure 21/298 (7.1) 43/1776 (2.4) <.0001
Any previous/ongoing CV medicationb 133/288 (46.2) 705/1741 (40.5) .07
Any antiplatelet medication 81/284 (28.5) 424/1726 (24.6) .15
Aspirin 74/284 (26.1) 406/1724 (23.6) .36
Clopidogrel 26/284 (9.2) 146/1723 (8.5) .70
Beta-blockers 58/277 (20.9) 279/1662 (16.8) .09
ACEi/ARB 63/277 (22.7) 329/1661 (19.8) .26
Statins 58/278 (20.9) 284/1662 (17.1) .13
Note: Values are n (%) unless indicated otherwise.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass
graft; CAD, coronary artery disease; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; IQR, interquartile range; PCI,
percutaneous coronary intervention; TIA, transient ischemic attack.
aIncludes all patients discharged on two or more antiplatelets (ie, including triple antiplatelet therapy) from the index hospitalization. DAPT duration is
defined as the time from discharge to the last use of two or more antiplatelets not accounting for interruptions.
bNumber affected/number with data available.
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2.3 | Statistical analysis
Baseline demographics and characteristics were compared according to
post-discharge DAPT duration ≤12 months vs >12 months up to 2 years
among NSTEMI patients discharged on DAPT who survived ≥12 months
post-discharge. P values were calculated using the chi-square test for
categorical variables, two-sample t-test for comparison of means, and
Wilcoxon test for comparison of medians. Patients on DAPT at discharge
include all those discharged on two or more antiplatelets (ie, including tri-
ple antiplatelet therapy) from the index hospitalization, and DAPT dura-
tion is defined as the time from discharge to the last use of two or more
antiplatelets, not accounting for interruptions.
In NSTEMI patients who survived at least the first 12 months post-
discharge, the incidence of major adverse cardiovascular events, death as
an individual item, and major bleeding events during the second year of
follow-up was also explored according to DAPT duration ≤12 months vs
>12 months. A major caveat is that causality cannot be inferred between
outcomes and DAPT duration since it was not a randomized study; DAPT
duration is not a baseline variable but an outcome, and there are multiple
possible confounders, particularly regarding the nonspecified selection
processes determining which patients stop or continue on DAPT at any
time point. Thus, patients with DAPT duration ≤12 or > 12 months
should not be considered treatment groups, but rather as different patient
groups with different clinical characteristics and risk profiles.
3 | RESULTS
3.1 | Patients
Of the 13 005 ACS survivors enrolled in EPICOR Asia, 12 922 met
the inclusion/exclusion criteria, of whom 6306 (48.8%) had a final diag-
nosis of NSTE-ACS at discharge, including 2549 (19.7%) with NSTEMI.
The mean age of NSTEMI patients was 62 years, 73.9% were male,
83.9% had at least one CV risk factor, 29.5% had prior CVD, and the
majority (76.5%) were of Asian ethnicity, as reported previously.17
3.2 | DAPT duration and patient characteristics
Among the 2549 NSTEMI patients, 2315 (90.8%) were discharged on
DAPT, of whom 490 (21.2%) stopped DAPT within the first year, and
TABLE 2 Antithrombotic management in NSTEMI patients
Time post-discharge (months)
Discharge 6 12 18 24
n = 2549 n = 2412 n = 2312 n = 2197 n = 2032
AP therapy, n (%)
DAPTa 2315 (90.8) 2051 (85.0) 1832 (79.1) 1429 (65.0) 1219 (60.0)
Aspirin + P2Y12i
b 2247 (88.2) 2009 (83.3) 1797 (77.7) 1399 (63.7) 1192 (58.7)
Other DAPT 68 (2.7) 42 (1.7) 35 (1.5) 30 (1.4) 27 (1.3)
SAPT 230 (9.0) 328 (13.6) 426 (18.4) 680 (31.0) 710 (34.9)
Aspirin only 111 (4.4) 198 (8.2) 286 (12.4) 538 (24.5) 576 (28.4)
P2Y12i
b 118 (4.6) 128 (5.3) 137 (5.9) 139 (6.3) 130 (6.4)
Other single AP 1 (0.04) 2 (0.1) 3 (0.1) 3 (0.1) 4 (0.2)
No AP therapy 4 (0.2) 33 (1.4) 54 (2.3) 88 (4.0) 103 (5.1)
AC therapy, n (%) 29 (1.1) 23 (1.0) 22 (1.0) 22 (1.0) 20 (1.0)
AC + AP 26 (1.0) 21 (0.9) 20 (0.9) 19 (0.9) 18 (0.9)
AC only 3 (0.1) 2 (0.1) 2 (0.1) 3 (0.1) 2 (0.1)
Death and loss to follow-up, n
Death (cumulative) — 71 127 162 191
Lost to follow-up (cumulative) — 66 110 190 326
AP therapy in patients discharged on DAPTa (n = 2315), n
(%)
— n = 2192 n = 2108 n = 2012 n = 1866
DAPT — 2051 (93.6) 1831 (86.9) 1427 (70.9) 1217 (65.2)
SAPT — 117 (5.3) 232 (11.0) 506 (25.2) 557 (29.9)
No AP therapy — 24 (1.1) 45 (2.1) 79 (3.9) 92 (4.9)
Abbreviations: AC, anticoagulant; AP, antiplatelet; DAPT, dual antiplatelet therapy; P2Y12i, P2Y12 receptor inhibitor; SAPT, single antiplatelet therapy.
aIncludes all patients discharged on two or more antiplatelets (ie, including triple antiplatelet therapy) from the index hospitalization. DAPT during
follow-up is defined as the use of two or more antiplatelets not accounting for interruptions.
b99% clopidogrel.
4 ZOU ET AL.
TABLE 3 In-hospital and discharge characteristics of NSTEMI patients who survived ≥12 months and received DAPT for ≤12 months vs
>12 months post-dischargea
Characteristic
DAPT durationa
P value≤12 months (n = 299) >12 months (n = 1825)
Symptom onset to admission, hours; median (IQR) 8.2 (3.0-22.8) 8.0 (2.8-20.7) .98
Admission to reperfusion, hours; median (IQR) 63.1 (18.5-139.5) 45.6 (7.9-122.8) .12
Symptom onset to reperfusion, hours; median (IQR) 72.9 (29.6-154.5) 59.3 (23.3-137.8) .06
Length of hospital stay, days; median (IQR) 9.0 (6.0-14.0) 8.0 (5.0-12.0) <.01
Killip class, n (%) .51
I 212 (70.9) 1319 (72.3)
II 55 (18.4) 271 (14.9)
III 15 (5.0) 108 (5.9)
IV 6 (2.0) 38 (2.1)
Missing 11 (3.7) 89 (4.9)
Left bundle branch block, n (%)b 2/286 (0.7) 30/1736 (1.7) .20
Ejection fraction, n (%) .76
<30% 5 (1.7) 34 (1.9)
30-40% 14 (4.7) 95 (5.2)
≥40% 196 (65.6) 1137 (62.3)
Missing 84 (28.1) 559 (30.6)
Laboratory measures, median (IQR)
White blood cell count, cells/mm3 8170 (6580-10 385) 8800 (6900-10 985) <.05
Initial creatinine, mg/dL 0.94 (0.76-1.13) 0.91 (0.79-1.12) 1.00
Glucose, mg/dL 122.0 (100.0-163.4) 120.0 (99.2-162.4) .61
Hemoglobin, g/dL 13.5 (12.2-14.7) 13.6 (12.3-14.9) .47
In-hospital reperfusion,b,c n (%) 143 (48.0) 1246/1805 (69.0) <.0001
In-hospital PCI/CABG,b n (%) 145 (48.7) 1253/1806 (69.4) <.0001
Number of dilated vessels, median (IQR) 1.0 (1.0-2.0) 1.0 (1.0–2.0) .85
Any DESb n (%) 127 (42.5) 1113/1825 (61.0) <.0001
In-hospital complications,d n (%)b 44 (14.9) 216/1815 (11.9) .14
Discharge characteristics
Anticoagulants at discharge, n (%) 2 (0.7) 12 (0.7) .98
Dependence at discharge, n (%) .41
No dependence 282 (94.3) 1681 (92.1)
Nonsevere dependence 16 (5.4) 134 (7.3)
Severe dependence 1 (0.3) 10 (0.6)
EQ-5D overall score, mean (SD) 77.4 (13.9) 76.8 (15.1) .48
EQ-5D simple score, n (%)b .74
0 185/298 (62.1) 1090/1824 (59.8)
1 38/298 (12.8) 254/1824 (13.9)
≥2 75/298 (25.2) 480/1824 (26.3)
Note: Values are n (%) unless indicated otherwise.
Abbreviations: CABG, coronary artery bypass graft; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; EQ-5D, EuroQol-5 Dimensions quality of life
questionnaire; IQR, interquartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention.
aIncludes all patients discharged on two or more antiplatelets (ie, including triple antiplatelet therapy) from the index hospitalization. DAPT duration is
defined as the time from discharge to the last use of two or more antiplatelets not accounting for interruptions.
bNumber affected/number with data available.
cPrimary PCI or thrombolysis.
dIncluded MI, recurrent ischemia, heart failure, cardiogenic shock, and arrhythmia.
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1832 (79.1%) continued. Among those discharged on DAPT, 2124
(91.7%) survived for at least 12 months thereafter: 299 (14.1%) of
these patients stopped within the first year, and 1825 (85.9%)
continued. Compared with patients who remained on DAPT for more
than 12 months, those who stopped DAPT sooner were older
(P < .05), less likely to be male (P < .01), and were more likely to have
diabetes (P < .01), a history of CVD (P < .05), or chronic renal failure
(P < .0001) (Table 1).
At discharge, DAPT consisted predominantly of aspirin plus a
P2Y12 receptor inhibitor (99% clopidogrel) (Table 2). After 12 and
24 months of follow-up, the number of patients on DAPT had
declined to 1832 (79.1%) and 1219 (60.0%) patients, respectively.
Only 18.4% and 34.9% of patients were on single antiplatelet therapy
(SAPT) at 12 and 24 months.
Among patients who survived ≥12 months post-discharge, no sig-
nificant differences were evident in time from symptom onset to
admission, or from symptom onset or admission to reperfusion by
DAPT duration of use, although patients who stopped DAPT early
had a longer median length of hospital stay (9 vs 8 days; P < .01)
(Table 3). Patients who underwent in-hospital reperfusion (primary
PCI or thrombolysis), in-hospital PCI/CABG, or drug-eluting stent
(DES) placement were more likely to continue on DAPT beyond
12 months (P < .0001 in each case). There were no significant
TABLE 4 Event rates over the following 12 months in NSTEMI
patients who survived ≥12 months, and received DAPT for
≤12 months or > 12 months post-discharge
Event
Event rate by DAPT duration,
n/N (%)
≤12 months
(n = 299)
>12 months
(n = 1825)
Composite of death, MI, and
stroke
30/283 (10.6) 54 (1751 (3.1)
Composite of death, MI,
stroke, and major bleeding
29/281 (10.3) 58/1750 (3.3)
Mortality 25/299 (8.4) 30/1825 (1.6)
Myocardial infarction 6/273 (2.2) 21/1766 (1.2)
Stroke 4/279 (1.4) 11/1810 (0.6)
Major bleeding 0 4/1824 (0.2)
Abbreviations: n/N, number affected/number with data available.
F IGURE 1 Cumulative incidence of, A, the
composite endpoint and, B, mortality over the
following 12 months in NSTEMI patients who
survived ≥12 months and received DAPT
for ≤12 months or >12 months post-discharge.*
The incidence of the composite endpoint, death,
MI, and stroke, over the second 12 months was
10.6% with DAPT ≤12 months and 3.1% with
DAPT >12 months, and the mortality rate was
8.4% and 1.6%, respectively
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differences in in-hospital CV complications, degree of dependence at
discharge, or EuroQol-5 Dimensions score between those who
stopped DAPT early or continued beyond 12 months.
3.3 | DAPT duration and outcomes
In the NSTEMI population who survived at least 12 months post-dis-
charge, the median (interquartile range) duration of DAPT in patients
who received it for ≤12 months and > 12 months was 219 (80-347)
and 718 (589-725) days, respectively. The incidence of the composite
endpoint, death, MI, and stroke, over the next 12 months was 10.6%
with DAPT ≤12 months and 3.1% with DAPT >12 months, and the
mortality rate was 8.4% and 1.6%, respectively (Table 4 and Figure 1).
There were only four patients with major bleeding, all in the DAPT
>12 months group.
4 | DISCUSSION
The results of this analysis of NSTEMI patients included in the EPI-
COR Asia study showed that the majority (90.8%) were discharged on
DAPT, 78.8% continued it for over 12 months, and 60.0% remained
on DAPT at the final 2-year follow-up visit. Patients who discontinued
DAPT within the first year appeared to be a higher-risk population, as
they were older, and more likely to have a history of CVD or renal
dysfunction. Conversely, patients treated with DAPT beyond 1 year
appeared to be at lower CV risk. This reflects the observed paradox
that higher-risk patients post-MI are less likely to persist with pre-
scribed medication.18 A recent Canadian observational study in 2034
acute MI patients (NSTEMI or STEMI) who had undergone PCI also
reported higher baseline risk among patients who discontinued DAPT
early compared with at least 12 months of treatment.19 In that study,
significant differences in baseline characteristics with shorter vs lon-
ger DAPT duration included older age, history of MI, heart failure, or
atrial fibrillation, and a higher Global Registry of Acute Coronary
Events (GRACE) score (all P < .001 for trend). The authors also
reported a higher incidence of a composite primary outcome (nonfatal
acute MI, unplanned coronary revascularization, stent thrombosis,
new or worsening heart failure, cardiogenic shock, or stroke) in
patients who discontinued DAPT in less than 6 weeks (P < .0001), and
6 weeks to <6 months (P = .02), but not for 6 months to <12 months
(P = .06) compared with DAPT ≥12 months, indicating that the highest
risk of events is in the earliest stages following an acute MI. This
appears to be reflected in the EPICOR Asia data, since most of the sig-
nificant differences in baseline characteristics between the shorter vs
longer DAPT duration populations either diminished or disappeared
when only the ≥12-month survivors were included in the analysis,
with the exception of male sex and chronic renal failure.
Recent observational studies have also examined DAPT duration
in NSTEACS patients in Asia, but their follow-up periods typically did
not exceed 1 year.20,21 For example, the Taiwan ACute CORonary
syndrome Descriptive registry (T-ACCORD), performed in 2004 to
2007, included 1331 survivors of hospitalization for NSTE-ACS (32%
NSTEMI and 68% UA).20 Here, the investigators reported that 62% of
patients were discharged on DAPT, but only 13% remained on DAPT
at 12 months, indicating weak implementation of treatment guide-
lines. Notably, however, persistence with DAPT for ≥9 months was
associated with a significantly lower 1-year cumulative mortality com-
pared with DAPT use for <9 months (P < .01 by log rank test).
Low adherence to guideline-based DAPT use was demonstrated
in a further study in Malaysia of 525 high-risk survivors of NSTE-ACS
(Malaysia-ACute CORonary syndromes Descriptive [ACCORD] study).
Here, more than 80% of patients were managed medically following
hospitalization with 48% discharged on DAPT; this declined to 32%
and 16% at 3 and 12 months, respectively.21 Although the authors did
not report on CV outcomes, this was a younger population than in
EPICOR Asia and a high-risk population with only 3% having no iden-
tifiable CV risk factor.
In fact, the high-risk population should be given longer duration
of DAPT than others, which was verified in THEMIS (The Effect of
Ticagrelor on Health Outcomes in diabetes Mellitus patients Interven-
tion Study).22 The results showed that patients aged 50 years or older
with stable CAD and diabetes, even without a history of MI or stroke,
had a lower incidence of ischemic CV events with long-term DAPT
(median duration 39.9 months) vs single aspirin therapy. The THEMIS-
PCI substudy showed that in the prespecified subgroup of patients
with diabetes, stable CAD, and previous PCI, long-term DAPT (median
duration 3.3 years) provided a favorable net clinical benefit, more so
than in patients without a history of PCI.23
In EPICOR Asia, the “real-world” trial, the incidence of major
adverse CV events, including mortality, during the second year of
follow-up among patients who survived at least the first year was
higher with ≤12 months of DAPT compared with >12 months of
DAPT. Furthermore, the higher incidence of the composite endpoint
in patients who received DAPT for up to 12 months appeared largely
driven by cumulative mortality. As stated earlier, however, a causal
relationship cannot be inferred between earlier DAPT discontinuation
and increased risk of subsequent events. In the “real-world” setting,
the reasons contributing to DAPT use and duration will be multifari-
ous. It is possible that at least some cases of early DAPT discontinua-
tion are driven by bleeding events, and patients at increased risk of
bleeding are also often at increased risk of ischemic events, and vice
versa.24 The results of other studies referred to above also suggest
that ACS patients who stop DAPT earlier, for any reason, are a poten-
tially high-risk group requiring careful monitoring and management.
4.1 | Limitations
Limitations of the present analysis include those usually applicable to
observational studies, such as the nonrandomized nature of the study
population. There is also the risk of immortal time bias; that is, bias
introduced by the study design in which an outcome cannot occur
during the specified period of follow-up.25 In this study, for example,
patients had to survive until the 12-month follow-up visit in order to
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be included in the prolonged DAPT group, necessarily inferring an
advantage for these patients. Such potential bias may be evident in
the somewhat counter-intuitive observation that NSTEMI patients
with a prior history of CVD in EPICOR Asia were more likely to dis-
continue DAPT early. This could be explained by the possibility that
their overall health was worse and they were more likely to have died
during the first 12 months and therefore had no opportunity to con-
tinue on DAPT for >12 months. Our analysis of baseline risk factors
did show that many of the significant differences between shorter vs
longer overall DAPT duration populations became less or nonsignifi-
cant when we focused on patients who survived the first 12 months.
It should also be noted that most patients were enrolled at well-
equipped centers, perhaps fostering greater uptake of evidence-based
guidelines, specifically, the use of DAPT.
Finally, while the reasons for DAPT discontinuation were not
reported, some may be suggested. For example, baseline data showed
that patients who were older, female, with low body mass index
(BMI), previous CVD, or renal insufficiency tended to stop DAPT
treatment soon after discharge. The early cessation of DAPT in the
older, low-BMI patients may be associated with bleeding, such as epi-
staxis and gingival bleeding. Although such bleeding is usually mild,
the patient may be very nervous and likely to stop DAPT as soon as
possible. Early discontinuation of drugs in women may be related to
lack of awareness of ACS disease, low family and social status, and
insufficient attention. In patients with previous CVD or renal insuffi-
ciency, early withdrawal of medication may be associated with too
many concomitant drugs or treatment with DAPT for a period prior to
study enrollment. Furthermore, in some cases, taking too much medi-
cine can cause stomach discomfort or ulcers. Sometimes, for example,
aspirin therapy may be stopped, either under the guidance of a doctor
or by the patient him/herself. As premature cessation of DAPT can
increase the risk of CV events, additional attention should be paid to
these groups, including patient education, increased follow-up fre-
quency, and close guidance on antiplatelet therapy and other
treatments.
5 | CONCLUSIONS
In summary, the majority of NSTEMI patients in EPICOR Asia were
discharged on DAPT, and nearly two-thirds remained on it at 2 years.
NSTEMI patients in whom DAPT treatment is stopped earlier than
12 months post-discharge appear to represent a vulnerable group in
terms of baseline risk factors and may benefit from more intensive
monitoring during long-term follow-up.
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